United Laboratories (03933.HK) receives second milestone payment from Novo under the exclusive licensing agreement for UBT251

Zhito Finance APP News: The United Laboratories (03933.HK) announced that on September 23, 2026, United Biotechnology received a global Phase I clinical milestone payment of US$9 million (after deduction of Danish withholding tax) from Novo for the UBT251 injection Type 2 diabetes indication.